Table 3.
Expression of studied genes in HCV-infected and non HCV-infected normal and malignant urothelium by real time PCR
| Normal urothelium without HCV | Normal urothelium with HCV | Malignant urothelium without HCV | Malignant urothelium with HCV | |
|---|---|---|---|---|
|
Telomerase : | ||||
|
• hTERT by RT-PCR |
0.13 ± 0.05 |
2.37 ± 0.44a |
6.16 ± 0.57 ab |
11.88 ±1.34 abc |
|
• hTERT by IH (+ve cases) |
3 (6%) |
12 (24%) |
24 (48%) |
38 (76%) |
| Mean labeled cells |
11.53 ± 2.82 |
14.90 ± 1.46 |
31.65 ± 9.02 |
44.36 ± 9.84 |
|
TRAP (ng/ml) |
0.54 ± 0.24 |
2.98 ± 0.59 a |
8.03 ± 1.26 ab |
15.88 ± 1.94 abc |
| (positive cases) |
2 (4%) |
10 (20%) |
32 (64%) |
41 (82) |
|
Tumour suppressor genes: | ||||
|
• Rb by RT-PCR |
11.27 ± 1.42 |
6.92 ± 0.81 a |
2.75 ± 0.65 ab |
0.32 ± 0.30 abc |
|
• Rb by IH (positive cases) |
3 (6%) |
12 (24%) |
26 (52%) |
40 (80%) |
|
• E2F3 by RT-PCR |
0.41 ±0.09 |
1.74 ± 0.47 a |
3.60 ±1.22 ab |
9.75 ± 4.32 abc |
|
• TP53 by RT-PCR |
0.25 ± 0.34 |
1.68 ± 0.29 a |
3.92 ± 0.46 ab |
12.39 ± 1.82 abc |
|
• p53 by IH (positive cases) |
0 (0%) |
3 (6%) |
21 (42%) |
42 (84) |
|
• P21 by RT-PCR |
9.80 ± 0.45 |
5.83 ± 0.86 a |
3.19 ± 0.45 ab |
0.25 ±0.34 abc |
|
• P21 by IH (positive cases) |
49 (98%) |
31 (62%) |
13 (26%) |
3 (6%) |
|
Protooncogenes: | ||||
|
• FGFR3 by RT-PCR |
0.08 ± 0.12 |
0.86 ± 0.76 |
3.06 ± 2.45 ab |
2.87 ± 3.88 ab |
| • FGFR3 by IH (positive cases) | 0 (0%) | 2 (4%) | 38 (76%) | 48 (96%) |
All data are expressed as Mean ± SD. One way ANOVA test with posthoc Scheffe’s test. a significant vs normal urothelium without HCV, b significant vs normal urothelium with HCV, C significant vs malignant urothelium without HCV (p< 0.05).